ONKOLOGIE / Onkologie. 2024;18(4):254-258 / www.onkologiecs.cz 258 HLAVNÍ TÉMA Nové cíle v léčbě karcinomu žaludku 15. Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624-7634. doi: 10.1158/1078-0432.CCR-08-1547. PMID: 19047087. 16. Türeci O, Sahin U, Schulze-Bergkamen H, et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019;30(9):1487-1495. doi: 10.1093/annonc/ mdz199. PMID: 31240302; PMCID: PMC6771222. 17. Sahin U, Türeci Ö, Manikhas G, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32(5):609-619. doi: 10.1016/j.annonc.2021.02.005. Epub 2021 Feb 19. PMID: 33610734. 18. Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655-1668. doi: 10.1016/ S0140-6736(23)00620-7. Epub 2023 Apr 15. Erratum in: Lancet. 2023;402(10398):290. doi: 10.1016/S0140-6736(23)01481-2. Erratum in: Lancet. 2024;403(10421):30. doi: 10.1016/S01406736(23)02762-9. PMID: 37068504. 19. Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133-2141. doi: 10.1038/s41591023-02465-7. Epub 2023 Jul 31. PMID: 37524953; PMCID: PMC10427418. 20. Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(10):1571-1580. doi: 10.1001/ jamaoncol.2020.3370. PMID: 32880601; PMCID: PMC7489405. 21. Wainberg ZA, Shitara K, Van Cutsem E, et al. Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial. JCO. 2022;40:243-243. doi: 10.1200/JCO.2022.40.4_suppl.243. 22. Janjigian YY, Ajani JA, Moehler M, et al. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024 Feb 21:JCO2301601. doi: 10.1200/JCO.23.01601. Epub ahead of print. PMID: 38382001. 23. Shitara K, Ajani JA, Moehler M, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942-948. doi: 10.1038/s41586-022-04508-4. Epub 2022 Mar 23. PMID: 35322232; PMCID: PMC8967713. 24. Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4. PMID: 29880231. 25. Chao J, Fuchs CS, Shitara K, et al. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol. 2021;7(6):895902. doi: 10.1001/jamaoncol.2021.0275. PMID: 33792646; PMCID: PMC8017478. 26. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4. PMID: 31682550; PMCID: PMC8184060. 27. Lordick F, Carneiro F, Cascinu S, et al. Electronic address: clinicalguidelines@esmo.org. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005-1020. doi: 10.1016/j.annonc.2022.07.004. Epub 2022 Jul 29. PMID: 35914639. 28. Muro K, Kawakami H, Kadowaki S. NO LIMIT study. Ann Oncol. 2023;43(Supplement 2):S852-S853. https://doi.org/10.1016/j.annonc.2023.09.1426. PŘEDPLATNÝM ČASOPISU NA ROK 2025 ZÍSKÁTE: 20% slevu na kongresy* pořádané společností SOLEN 20% slevu na předplatné časopisu Onkologie při úhradě do 15. 12. 2024 Tematická suplementa Přístup do archivu časopisu on-line * platí pro kongresy uvedené v seznamu Objednávejte www.onkologiecs.cz predplatne@solen.cz Dvojitá sleva, dvojitá výhoda! Uhraďtepředplatné (5 čísel/rok) do 15. 12. 2024 za cenu: 1 350 Kč 1 080 Kč
RkJQdWJsaXNoZXIy NDA4Mjc=